Strategic partnership · ecosystem
The connective layer for UAE's genomic health economy.
A note for the teams building the UAE's health infrastructure — on where AGenomics fits, why this category can be defined here rather than imported, and what a co-designed pilot pathway could look like.
Hub71 · M42 · Emirates Genome Programme
The partnership thesis
The connective layer between platform and launchpad.
M42 and Hub71 have built the two things a genomic-medicine ecosystem needs most: a globally significant health and genomics platform, and a launchpad for the companies that will operate on top of it. AGenomics is the connective layer between them — the piece that turns the Emirates Genome Programme's data into daily clinical and financial outcomes across hospitals.
Just as Stripe let a generation of companies build on payments infrastructure they no longer had to create, AGenomics lets hospitals, insurers, and health-tech builders build on genomic infrastructure without standing up bioinformatics, payer integration, or HIE plumbing themselves — the natural next step.
Positioned in Abu Dhabi, aligned with national programmes, and designed for the exact regulatory and HIE reality this ecosystem runs on.
Infrastructure, not a single product
Hospitals, insurers, and health-tech builders can build on genomic infrastructure without standing up bioinformatics, payer integration, or HIE plumbing themselves.
Anchored in Abu Dhabi
Positioned in Abu Dhabi, aligned with national programmes, and designed for the exact regulatory and HIE reality this ecosystem runs on.
Compounds with every hospital
Strategic value grows with each hospital that joins, through federated intelligence that improves the whole network without ever pooling patient records.
Why co-build here
A category the UAE is uniquely positioned to own.
No US or European health-tech company has UAE HIE access, UAE payer relationships, or an Arab-population genomic dataset to build against — and none can acquire all three quickly, because they come only from operating inside the market and earning hospital and regulatory trust first. That makes this a category the UAE can define and own rather than import.
For M42, AGenomics extends the reach of the national genome investment into the point of care and the point of billing. For Hub71, it is infrastructure other startups build on — a multiplier, not a single product.
The strategic value compounds with every hospital that joins, through federated intelligence that improves the whole network without ever pooling patient records.
Let's map the integration points together.
We would welcome the opportunity to connect with the Hub71 and M42 teams to explore the possibility — and co-design the pilot.